Core Insights - The company reported a strong FY 2025 with a constant-currency revenue growth of 24.2%, slightly above the prior guidance of 20% to 23% [2][7] - A leadership transition occurred with co-founder Gordon Sanghera stepping down as CEO, succeeded by Francis Van Parys, while Sanghera will remain as an advisor until early 2027 [4][8] - The company is focusing on applied markets, which now represent approximately 34% of revenue, with significant growth in clinical (59%), biopharma (30%), and applied industrial (27%) segments [1][7] Financial Performance - FY 2025 revenue from life science research tools constituted 66% of total revenue, growing by 15% [1] - The reported gross margin for FY 2025 was 58.6%, with a "see-through" gross margin closer to 61% [6][10] - The adjusted EBITDA loss improved by £31.2 million (26%), with a target for adjusted EBITDA breakeven in 2027 and cash flow breakeven in 2028 [6][14] Strategic Focus and Product Portfolio - The company is realigning its product portfolio, discontinuing P2 Solo and pausing the Elise platform, while increasing focus on integrated systems like P2i and P24 [8][21] - A strategic review identified $13 billion to $14 billion in higher-priority segments, shaping resource allocation and product roadmap decisions [18] - The company aims to enhance its value proposition through direct sequencing of native DNA and RNA, real-time data generation, and avoiding batching requirements [9] 2026 Guidance - For FY 2026, the company guided for revenue growth of 21% to 25%, with a gross margin target of 62% [22][24] - Growth is expected to be strongest in the Americas, with over 50% of revenue from applied segments, while challenges are anticipated in EMEA and APAC due to contract roll-offs and local competition [23] - The company expects adjusted OpEx growth of 0% to 5%, reflecting benefits from recent restructuring and efficiency initiatives [24]

Group 1 - The article does not provide any specific content related to a company or industry [1]